A month has gone by since the last earnings report for Corcept Therapeutics (CORT Quick QuoteCORT - Free Report) . Shares have lost about 1.2% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Corcept due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

Corcept Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised

Corcept reported second-quarter 2026 earnings of 36 cents per share, outperforming the Zacks Consensus Estimate of a loss of 4 cents. In the year-ago quarter, the company reported earnings of 29 cents.

Second-quarter revenues rose nearly 32% year over year to $256.1 million and surpassed the Zacks Consensus Estimate of $216 million. Growth was driven by higher Korlym sales and contribution from the newly launched product, Lifyorli (relacorilant).

Quarter in Detail

Corcept’s top line consisted of product sales from Cushing’s syndrome drug Korlym and newly launched ovarian cancer drug Lifyorli.

In the second quarter of 2026, product revenues from Korlym were $208.6 million, up 7.3% year over year. However, the metric missed our model estimate of $212.2 million.

Lifyorli generated $47.6 million in the second quarter of 2026, reflecting its first quarter of commercial sales.

Second-quarter operating expenses increased 28.1% year over year to $214.8 million. The rise reflected spending related to the Lifyorli launch and continued investment in the company’s Cushing’s syndrome business.

Selling, general and administrative expenses surged 51.1% to $156.9 million. Research and development expenses declined 10.9% to $53.9 million.

Corcept ended the June quarter with cash and investments of $544.6 million, up from $515.4 million as of March 31, 2026.

2026 Revenue Outlook

Corcept raised its 2026 revenue guidance to $1.1-$1.2 billion from the previous $950 million to $1.05 billion. Management said that the revised outlook reflects strength across the endocrinology and oncology businesses.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted 86.02% due to these changes.

VGM Scores

Currently, Corcept has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Corcept has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Corcept belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Summit Therapeutics PLC (SMMT Quick QuoteSMMT - Free Report) , has gained 6.6% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Summit Therapeutics reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$0.28 for the same period compares with -$0.76 a year ago.

For the current quarter, Summit Therapeutics is expected to post a loss of $0.28 per share, indicating a change of +9.7% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

Summit Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.